Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2012, with the report issued on January 9, 2012. The document details the initial outcomes from pivotal Phase III clinical studies for Relovair (fluticasone furoate/vilanterol), a once-daily investigational medicine developed in collaboration with Theravance, Inc. for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and asthma.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory strategy.
Material Changes and Clinical Outcomes
The filing reports the completion of the Phase III registration program for Relovair in COPD and the completion of all but one pivotal study in asthma. Key clinical findings include:
- COPD Programme: Two 52-week exacerbation studies involving approximately 3,240 patients showed that all doses of Relovair demonstrated reductions in the annual rate of moderate to severe exacerbations compared to vilanterol alone. Statistical significance was achieved at all doses in the first study, while the second study showed significance at the 100/25mcg dose but not the highest dose. GSK plans to request regulatory review of the totality of data for the 100/25mcg dose.
- Asthma Programme: Studies involving approximately 2,000 patients demonstrated that Relovair 100/25mcg significantly increased time to first severe exacerbation and decreased the annual rate of severe exacerbations compared to fluticasone furoate alone. Lung function improvements were also observed.
- Safety: Common adverse events included nasopharyngitis, upper respiratory tract infection, and headache. GSK is investigating reports of fatal pneumonia primarily at the 200/25mcg dose in COPD studies. No asthma-related deaths were reported in the asthma studies.
- Comparative Efficacy: In non-pivotal studies comparing Relovair to Seretide (fluticasone propionate/salmeterol), Relovair did not meet the predefined threshold for superiority in lung function endpoints, though no statistical difference was found between the treatments.
Guidance, Outlook, and Risks
Regulatory Outlook: GSK intends to commence global regulatory filings for Relovair in mid-2012. Applications are planned for the US and Europe for COPD, and Europe for asthma. Discussions with the FDA regarding US asthma indications will continue.
Future Development: GSK plans to continue development programs, including a 16,000-patient outcomes study in COPD patients with cardiovascular risk and pre-registration real-world effectiveness studies.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include potential delays in clinical studies, failure to achieve regulatory approval, safety concerns (specifically the ongoing investigation into fatal pneumonia reports), and reliance on third-party manufacturers. The filing notes that the investigational medicine is not currently approved anywhere in the world.
Investor Verification Checklist
- Verify the timeline for regulatory submissions in mid-2012 for both COPD and asthma indications.
- Monitor the outcome of the integrated safety analysis regarding fatal pneumonia reports at the 200/25mcg dose.
- Confirm the status of FDA discussions regarding the US asthma indication, as the filing notes this is still under discussion.
- Review the full data presentation at future scientific meetings to assess the robustness of the exacerbation reduction claims.
- Track the progress of the 16,000-patient outcomes study for COPD survival and cardiovascular risk.